W. Michael Gallatin, Ph.D.

President

Michael Gallatin has been President and a member of the Board of Directors since he co-founded Calistoga Pharmaceuticals in March 2006. Dr. Gallatin has more than 25 years of research and development experience in oncology, immunology, and vascular biology. Dr. Gallatin was one of the founding scientists at ICOS Corporation in 1990, most recently serving as Vice President and Scientific Director of ICOS Corporation before it was acquired by Eli Lilly and Company. Prior to joining ICOS, Dr. Gallatin was a faculty member of the Fred Hutchinson Cancer Research Center in Seattle, and an affiliate faculty member of the Department of Microbiology and Immunology at the University of Washington. He has been a member of the Scientific Advisory Board of the Keystone Symposia and Caprion and currently serves in that capacity for Stromedix Corporation and the University of Texas Department of Chemistry. He is a member of the BioSeek and Seredigm Boards of Directors. Dr. Gallatin also is a Venture Partner to the Biopharma team of Frazier Healthcare Ventures.

Dr. Gallatin received his Bachelor of Science in Zoology from Truman State University and was awarded a doctorate in Immunology from the University of Alberta, Department of Immunology. He undertook his postdoctoral training at Stanford University in the laboratory of Dr. Irving Weissman.